MedTrace Logo

Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia

NCT03631719 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 834

Last updated 2022-04-08

No results posted yet for this study

Summary

Study setting: Medellin and Bello municipalities, Colombia Health condition(s) studied: Dengue, Zika and chikungunya virus infection Intervention: Deployment of Wolbachia-infected Aedes aegypti mosquitoes in Medellin and Bello.

Study design:

1. An interrupted time-series analysis utilising routine disease surveillance data collected by the Medellín and Bello Health Secretariats, which aims to compare incidence of dengue, chikungunya and Zika pre- and post-Wolbachia release.
2. A test-negative study using an incident case-control design, which aims to quantify the reduction in disease incidence among people living within a Wolbachia-treated zone compared with an untreated zone that has a similar dengue risk profile at baseline.

Conditions

  • Dengue
  • Chikungunya Virus Infection
  • Zika Virus Infection

Interventions

BIOLOGICAL

Wolbachia-carrying Ae.aegypti mosquitoes

Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).

Sponsors & Collaborators

  • Monash University

    collaborator OTHER

  • United States Agency for International Development (USAID)

    collaborator FED

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • Universidad de Antioquia

    lead OTHER

Principal Investigators

  • Cameron Simmons, Prof. · Monash University

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-25
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03631719 on ClinicalTrials.gov